New NHS Drug Mirvetuximab Soravtansine Extends Ovarian Cancer Patient Lives by Months
A breakthrough pharmaceutical, mirvetuximab soravtansine, has been approved for NHS use, marking the first new treatment for advanced ovarian cancer in two decades. This drug, developed by AbbVie, operates as a "biological missile," targeting cancerous tissue directly and thereby mitigating the severe side-effects associated with conventional chemotherapy.
Patricia Hill, 64, from North London, a patient benefiting from the new treatment, described the improvement as "like night and day," allowing her to resume activities such as theatre visits and family gatherings previously impossible due to debilitating side-effects. The therapy has reportedly given her "a lot of my life back," with significantly reduced fatigue and sickness compared to standard regimens.
Targeted Treatment for Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine is designed to target cancer cells expressing folate receptor alpha, a marking found on approximately 30-40% of ovarian cancers resistant to platinum-based chemotherapy. The drug delivers a toxic payload directly into these cells, minimising harm to healthy tissue. Clinical trials, including participation from patients like Jenny Green, 71, of Hertfordshire, demonstrated tumour shrinkage and improved blood markers with minimal side-effects.
The National Institute for Health and Care Excellence (NICE) has approved the drug for ovarian, peritoneal, and fallopian tube cancers where chemotherapy is no longer effective and the specific cellular markers are present. NHS England has confirmed funding, with Wales and Northern Ireland expected to follow suit, while Scotland will make an independent decision.
Dr. Rowan Miller, who led clinical trials at UCLH, expressed enthusiasm for the drug's availability, highlighting its ability to improve survival and patient tolerance. Professor Ruth Plummer, NHS national clinical lead for cancer drugs, heralded it as the "most significant breakthrough" for these difficult-to-treat cancers in over two decades, a sentiment echoed by ovarian cancer support charities Ovacome and Target Ovarian Cancer, who welcomed the expanded treatment options for women with platinum-resistant ovarian cancer.
